Patient consent form relating to a UK clinical trial of Glivec (Imatinib), 2001

Consent form to participate in the STI571 clinical trial of the targeted therapy Glivec (imatinib) in patients with Chronic Myeloid Leukaemia (CML), signed by Doreen Eggleton, 3rd October 2001. This was the copy of consent kept by the patient.

Doreen Eggleton was diagnosed with the blood cancer Chronic Myeloid Leukaemia (CML) in 1998. At the time treatment options for this disease were limited, however in 2001 Doreen became one of the participants on the first UK clinical trial of a new, effective targeted therapy drug called Glivec (imatinib). This was the form Doreen signed, to give her consent to participate in the trial. Clinical trials are the way the safety and efficacy of new treatments can be compared to exisiting therapies. Trial participants must give their consent to show they are willing to be entered into a trial.

Glivec (imatinib) is a type of cancer growth blocker called a tyrosine kinase inhibitor (TKI). Tyrosine kinases are proteins that cells use to signal to each other to grow. They act as chemical messengers and blocking them stops the cancer cells growing.